Skip to main content
Contact Us
Subscribe
E-Edition
72°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by uniQure Inc.
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
February 28, 2024
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
December 19, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
November 29, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 07, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
October 24, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
October 05, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
September 05, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 01, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
June 26, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
June 21, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
June 20, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
ASX:CSL
QURE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
May 15, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 02, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure to Participate in Multiple Upcoming Industry Conferences in March
March 02, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
February 27, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
February 23, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
ASX
QURE
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
February 21, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
ASX
QURE
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
January 31, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 20, 2022
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
December 16, 2022
From
uniQure Inc.
Via
GlobeNewswire
Tickers
ASX:CSL
QURE
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
November 29, 2022
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure announces FDA approval of first gene therapy for adults with hemophilia B
November 22, 2022
From
uniQure Inc.
Via
GlobeNewswire
Tickers
ASX:CSL
QURE
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
November 17, 2022
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 02, 2022
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.